Skip to main
XTNT

XTNT Stock Forecast & Price Target

XTNT Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Xtant Medical Holdings is a medical technology company with a diverse portfolio of orthobiologics and spinal implant systems that is expected to generate strong revenue growth driven by sales of new products and increasing distributor interest. With a discount to peer valuations, a strong cash position, and opportunities for continued growth and profitability, Xtant presents a promising investment opportunity in the small-cap orthobiologics market.

Bears say

Xtant Medical Holdings is heavily reliant on the US market and faces intense competition in the medical technology industry. Despite its recent acquisition of Dilon Technologies and HEMOBLAST distribution rights, the company is still struggling to generate revenue and improve its gross margins. Additionally, the shift towards a focus on Orthobiologics may not yield significant results in the near term, and the company may need to raise more capital in the future. These risks, combined with a softer procedure environment, may hinder the company's ability to meet its revenue targets and could lead to a decline in share price.

XTNT has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Xtant Medical Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Xtant Medical Holdings (XTNT) Forecast

Analysts have given XTNT a Strong Buy based on their latest research and market trends.

According to 1 analysts, XTNT has a Strong Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Xtant Medical Holdings (XTNT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.